SCHEMBL26316639

SCHEMBL26316639

Cc1ccc(/C=C/c2nc(COc3ccc(CCCCOC(=O)N(C)C)cc3)co2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 3/20 0.51
MINK1 Q8N4C8 1/20 0.51
FFAR1 O14842 4/20 0.38
PPARA Q07869 4/20 0.37
PPARG P37231 3/20 0.37
LTB4R Q15722 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37
ATP4A P20648 2/20 0.35
ATP4B P51164 2/20 0.35
CYSLTR2 Q9NS75 1/20 0.34
CYSLTR1 Q9Y271 1/20 0.34
NPC1 O15118 1/20 0.34
CASP3 P42574 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
APP P05067 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26316636 0.92 ERBB2 (0.48) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL22397971 0.90 ERBB2 (0.64) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL22397974 0.90 ERBB2 (0.64) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL26316666 0.88 ERBB2 (0.51) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL26316711 0.88 ERBB2 (0.53) ERBB2MINK1
SCHEMBL26316563 0.85 ERBB2 (0.54) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL26316662 0.84 ERBB2 (0.53) ERBB2MINK1FFAR1PPARAPPARG
SCHEMBL26316637 0.83 ERBB2 (0.47) ERBB2MINK1NPC1RAB9ASMN1; SMN2
SCHEMBL22398096 0.82 ERBB2 (0.61) ERBB2MINK1PPARAPPARG
SCHEMBL22398095 0.82 ERBB2 (0.61) ERBB2MINK1PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 ERBB2 2558/4885MINK1 1781/4885FFAR1 4743/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 ERBB2 2443/4885MINK1 1986/4885FFAR1 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.